Conversion Rate of Essential Tremor to Essential Tremor-Parkinson’s Disease: Data from a Prospective, Longitudinal Study

Characterizing Lewy Pathology in 231 Essential Tremor Brains from the Essential Tremor Centralized Brain Repository

Results from the first four regimens of the HEALEY ALS Platform Trial

Author:Paganoni, Sabrina   Berry, James   Quintana, Melanie   Macklin, Eric   Saville, Benjamin   Andrews, Jinsy   Shefner, Jeremy   Fournier, Christina   Babu, Suma   Maragakis, Nicholas   Oskarsson, Bjorn   Detry, Michelle   Chase, Marianne   Sherman, Alex   Yu, Hong   Pothier, Lindsay   Drake, Kristin   Chibnik, Lori   Bind, Marie-Abele   Vestrucci, Matteo   McGlothlin, Anna   Marion, Joseph   Duda, Petra   Harvey, Brittany   Qureshi, Irfan   Donohue, Mary   Granit, Volkan   Grossman, Katheryn   Glanzman, Robert   Hotchkin, Michael   Goldberg, Y Paul   Leitner, Melanie   Hayden, Michael   Cudkowicz, Merit   

Session Name:PL5: Clinical Trials Plenary Session  

Topic:Neuromuscular and Clinical Neurophysiology (EMG)  

Program Number:PL5.004  

Author Institution:Massachusetts General Hospital, Boston, MA  Berry Consultants, Austin, TX  MGH Biostatistics Center, Boston, MA  Columbia University Medical Center, New York, NY  Barrow Neurological Institute, Phoenix, AZ  Emory University, Atlanta, GA  Johns Hopkins University School of Medicine, Baltimore, MD  Mayo Clinic, Jacksonville, FL  Harvard School of Public Health, Boston, MA  UCB, Brussels, Belgium  Biohaven Pharmaceuticals, New Haven, CT  Biohaven Pharmaceuticals, Inc., New Haven, CT  Biohaven Pharmaceuticals, East Petersburg, PA  Clene Nanomedicine Inc, Holladay, UT  Clene Nanomedicine, Inc., Salt Lake City, UT  Prilenia Therapeutics, Herzliya, Israel  Accelerating Neuroventures, Boston, MA